The association between vitamin intake and the progression of metabolic dysfunction-associated fatty liver disease
10.3969/j.issn.1006-5725.2024.06.015
- VernacularTitle:维生素摄入量与代谢相关脂肪性肝病进程的相关性分析
- Author:
Renling YAO
1
;
Yixuan ZHU
;
Rui HUANG
;
Jie LI
Author Information
1. 南京大学医学院附属鼓楼医院感染科(南京 210008)
- Keywords:
metabolic dysfunction-associated fatty liver disease;
liver fibrosis;
mortality;
vitamin
- From:
The Journal of Practical Medicine
2024;40(6):820-826
- CountryChina
- Language:Chinese
-
Abstract:
Objective There is a Few studies explored the association between vitamin intake and meta-bolic dysfunction-associated fatty liver disease(MAFLD),while the existing results were still contradictory.This study aimed to investigate the association between dietary vitamins and all-cause mortality as well as fibrosis risk in patients with MAFLD.Methods The data were extracted from the third National Health and Nutrition Examination Surveys 1988-1994.Dietary vitamins was assessed using a 24 h diet recall,including vitamin A,vitamin B6,vitamin B12,vitamin C,vitamin D,thiamin,riboflavin,folic acid and α-tocopherol.The non-alcoholic fatty liver disease fibrosis score(NFS)<-1.455 was considered as non-advanced fibrosis,while NFS≥-1.455 was considered as advanced fibrosis.Results A total of 3844 MAFLD participants were included in this study.The median time of follow-up was 310 months.1739 participants(45.3%)were deceased during the follow-up.The intake of thiamin,riboflavin,α-tocopherol,VB6,and VB12 were significantly higher in patients with NFS-determined non-advanced fibrosis(P<0.05).After adjusting,a significantly lower risk of fibrosis was found in patients with the highest quartile(>11.5 mg/d)of α-tocopherol intake compared to the lowest intake group(P = 0.031).Compared to the lowest quartile group,the risk of mortality was reduced by 0.34 folds in the group consuming the highest quartile amount(>130 mg/d)of VC(HRs:0.66,95%CI:0.51～0.85,P = 0.001).Conclusions More α-tocopherol intake reduced fibrosis grade in MAFLD patients.VC intake may reduce all-cause mortality in patients with MAFLD.
